# Quality Score Report: ADR-001 NPT-014 Elimination Policy

## L0 Executive Summary

**Score:** 0.9185/1.00 | **Verdict:** REVISE | **Weakest Dimension:** Evidence Quality (0.90)
**One-line assessment:** ADR-001 is a well-structured, methodologically rigorous architecture decision record that misses the C4 threshold (0.95) primarily due to evidence presentation opacity and two specific consistency gaps; targeted improvements to evidence specificity and the minor redundancy issue will raise the score to threshold.

---

## Scoring Context

- **Deliverable:** `projects/PROJ-014-negative-prompting-research/orchestration/neg-prompting-20260227-001/phase-5/ADR-001-npt014-elimination.md`
- **Deliverable Type:** ADR (Architecture Decision Record)
- **Criticality Level:** C4
- **C4 Threshold:** 0.95 (elevated from standard H-13 threshold of 0.92)
- **Scoring Strategy:** S-014 (LLM-as-Judge)
- **SSOT Reference:** `.context/rules/quality-enforcement.md`
- **ADR Gate Checks Applied:** GC-ADR-1 through GC-ADR-5
- **Strategy Findings Incorporated:** No (standalone I1 scoring)
- **Iteration:** I1 (first scoring)
- **Scored:** 2026-02-28T00:00:00Z

---

## Score Summary

| Metric | Value |
|--------|-------|
| **Weighted Composite** | 0.9185 |
| **C4 Threshold** | 0.95 |
| **Standard H-13 Threshold** | 0.92 |
| **Verdict** | REVISE |
| **Strategy Findings Incorporated** | No |
| **FMEA Arithmetic Verified** | YES — all 5 RPN values correct |
| **L2 Token Budget Arithmetic Verified** | YES — 745/850 = 87.6% correct |

---

## Gate Check Results

| Gate | Description | Status | Evidence |
|------|-------------|--------|----------|
| GC-ADR-1 | Nygard format compliance (Title, Status, Context, Decision, Consequences) | PASS | All 5 required sections present; extended with L0/L1/L2, Forces, Options, Compliance |
| GC-ADR-2 | Evidence tier labels on all claims | PASS (with gap) | Compliance section has explicit 6-row tier table; minor: A-31 lacks title/author |
| GC-ADR-3 | PG-003 reversibility assessment present | PASS | Full 5-component reversibility table; HIGH overall; null-framing contingency documented |
| GC-ADR-4 | Phase 2 dependency correctly handled | PASS | Explains unconditional status with 3 independent sources; "PG-001 unconditional, Phase 2 outcome irrelevant" explicitly stated |
| GC-ADR-5 | No false validation claims | PASS | MANDATORY EPISTEMOLOGICAL BOUNDARY stated at line 86; UNTESTED label applied to NPT-009 vs. positive framing; A-11 absent throughout |
| A-11 check | A-11 (hallucinated citation) absent | PASS | Zero occurrences; C-001 constraint entry explicitly prohibits it |
| AGREE-5 check | AGREE-5 not presented as T1/T3 | PASS | Labeled "internally generated, NOT externally validated" in Background; not cited as peer-reviewed evidence anywhere |

---

## Dimension Scores

| Dimension | Weight | Score | Weighted | Evidence Summary |
|-----------|--------|-------|----------|-----------------|
| Completeness | 0.20 | 0.93 | 0.1860 | All Nygard sections + L0/L1/L2 + 4 adversarial strategies + sequencing protocol; AGREE-5 caveat present |
| Internal Consistency | 0.20 | 0.91 | 0.1820 | Strong claim alignment with upstream; minor: Group 2 description uses two count formats (27+5 vs. 32); minor Consequences redundancy |
| Methodological Rigor | 0.20 | 0.93 | 0.1860 | S-003/S-004/S-012/S-013 applied; FMEA arithmetic verified correct; token budget arithmetic verified correct |
| Evidence Quality | 0.15 | 0.90 | 0.1350 | T1/T3/T4/UNTESTED labels correct; A-11 absent; AGREE-5 not over-cited; A-31 lacks bibliographic specificity |
| Actionability | 0.15 | 0.91 | 0.1365 | 5-step upgrade procedure; 4-group sequencing; Phase 2 baseline protocol; concrete examples; specific upgrade targets referenced by code |
| Traceability | 0.10 | 0.93 | 0.0930 | 13-entry reference table; constraint-to-source mapping; claim-to-tier-to-source table; PS Integration worktracker linkage |
| **TOTAL** | **1.00** | | **0.9185** | |

**H-15 Arithmetic Verification:**
- 0.1860 + 0.1820 = 0.3680
- 0.3680 + 0.1860 = 0.5540
- 0.5540 + 0.1350 = 0.6890
- 0.6890 + 0.1365 = 0.8255
- 0.8255 + 0.0930 = **0.9185** (confirmed)

**Distance from C4 threshold:** 0.95 − 0.9185 = **0.0315** (approximately 3 dimension-point improvements of 0.10 each would close this gap)

---

## Detailed Dimension Analysis

### Completeness (0.93/1.00)

**Evidence:**

The ADR meets or exceeds all structural requirements for a C4 Nygard ADR. Present sections: Title, Status (PROPOSED), Context (with problem statement, background, evidence base, NPT-014 definition), Constraints table (C-001 through C-007), Forces (4 tensions with explicit reasoning), Options Considered (3 options each with Steelman/Pros/Cons/Fit with Constraints), Decision (with 4-point rationale and alignment table), L1 Technical Implementation (diagnostic filter, 5-step upgrade procedure, 4-group sequencing, Phase 2 baseline protocol, L2 token budget analysis), L2 Architectural Implications (maturity progression, systemic consequences, Pre-Mortem, FMEA, Inversion), Consequences (positive 5 entries, negative 5 entries, neutral 3 entries, risks 6 entries), Compliance (PG-003 reversibility table, evidence tier table, constraint propagation verification), Related Decisions, References (13 entries), PS Integration, Self-Review Checklist (H-15, 17 checks).

All four gate checks that have completeness implications pass (GC-ADR-1 through GC-ADR-5).

The AGREE-5 caveat ("internally generated, NOT externally validated") appears in the Background section at line 64 — matching the mandatory caveat established in barrier-4/synthesis.md v4.0.0 revisions.

**Gaps:**

1. Group 2 implementation description uses inconsistent count framing: the Decision section says "27 agent-level + 5 framework-level" but the barrier-4/synthesis.md source shows "32 recommendations across 9 agent families." The arithmetic is consistent (27+5=32) but the "framework-level" sub-category is not defined elsewhere, creating a potential reader confusion point. This is a minor completeness gap in the implementation definition.

2. The 6 specific rule-file upgrade recommendations (R-QE-001 through R-ADS-003, cited at line 274) are referenced by code but not listed or summarized in the ADR. An implementer must read TASK-012 to get the specific targets. For an ADR this is acceptable, but a brief enumeration (even just titles) would prevent implementation ambiguity.

**Improvement Path:**

Add one sentence clarifying what "framework-level" agent recommendations means in Group 2 context. Optionally add a compact table listing the 6 rule-file recommendations by ID and short description in the L1 section, reducing the need to cross-reference TASK-012.

---

### Internal Consistency (0.91/1.00)

**Evidence:**

The ADR's central logic is coherent and consistent throughout: T1+T3 evidence establishes blunt prohibition underperforms → PG-001 is unconditional → Phase 2 outcome is irrelevant for NPT-014 elimination → universal policy applies. This chain is stated in L0 (lines 40-48), repeated in Context/Evidence Base (line 86-98), reinforced in Decision/Rationale (lines 210-216), and validated in Compliance (lines 447-453). No contradiction exists in the core argument.

Evidence tier assignments are consistent with upstream documents. Barrier-2/synthesis.md L0 confirms "Blunt standalone prohibition underperforms structured alternatives (T1 evidence)" — matching the ADR's T1 claim for A-20 and A-15. Barrier-4/synthesis.md L0 confirms "NPT-014 elimination (blunt prohibition upgrade) is the one action supported by T1+T3 unconditional evidence (PG-001)" — matching the ADR's decision rationale.

The Self-Review Checklist at lines 530-548 has 17 checks all marked PASS. The MANDATORY EPISTEMOLOGICAL BOUNDARY at line 86-87 is maintained throughout — no instance of the ADR claiming NPT-009 outperforms positive equivalents.

**Gaps:**

1. **Redundant risk documentation.** The Pre-Mortem table (lines 349-355, 5 rows with Why/Mitigation columns) substantially overlaps the Consequences: Risks table (lines 459-466, 6 rows with Probability/Impact/Mitigation columns). The failure modes are nearly identical: formulaic consequence documentation, Phase 2 baseline contamination, implementation stall, new NPT-014 introduction, L2 token budget overrun. This redundancy is not a contradiction, but it creates an internal consistency question: which table is authoritative? The L2 Architectural Implications section (Pre-Mortem) and the standalone Consequences: Risks section contain the same information with slightly different probability assessments in two places.

2. **Minor framing inconsistency in Option evaluation.** The Options Evaluation Summary table scores Option 1 "9/10" but the scoring criteria are not defined — it is unclear whether 9/10 means "this option is 90% optimal" or some other scale. The prose around the table does not define the scale, making the numeric scores impressionistic rather than derived.

**Improvement Path:**

Consolidate the Pre-Mortem table and Consequences: Risks table into a single table, or clearly differentiate them by scope (Pre-Mortem = failure mode discovery methodology; Consequences: Risks = formal risk register). Add a note to the Options Evaluation Summary table clarifying the scoring basis (e.g., "Score = alignment with evidence breadth + implementation feasibility + Phase 2 compatibility, each 0-3, summed").

---

### Methodological Rigor (0.93/1.00)

**Evidence:**

Four adversarial quality strategies are applied and documented:

- **S-003 (Steelman):** Applied to all three options. Each rejected option includes a genuine steelman paragraph that acknowledges the option's strongest form. Option 2's steelman ("Rule files are the highest-impact domain... focuses effort where the evidence is most directly applicable") is particularly well-constructed.
- **S-004 (Pre-Mortem):** Table at lines 349-355 with 5 failure modes, probability ratings, and specific mitigations. Not generic — "Consequence specificity standard: consequences MUST name the specific failure mode" is a specific, enforceable standard.
- **S-012 (FMEA):** Table at lines 359-366 with Severity, Occurrence, Detection, RPN, and Mitigation. All 5 RPN calculations verified correct (72, 48, 100, 150, 28). Highest RPN correctly identified (150: new NPT-014 introduction).
- **S-013 (Inversion):** Lines 371-380. The inversion ("mandate that all constraints remain as blunt prohibitions") is properly reasoned and reveals 5 specific consequences that confirm the policy direction.

The epistemological methodology is rigorous: the explicit distinction between "what is established" (T1 blunt prohibition underperforms) and "what is untested" (NPT-009 vs. positive framing) is maintained as a structural discipline throughout, not just stated once.

The NPT-014 diagnostic filter (lines 233-240) provides binary classification criteria. The 5-step upgrade procedure (lines 244-266) is methodologically complete.

**Gaps:**

1. The FMEA's Detection column values are not explained. A Detection value of 2 means "very unlikely to detect before harm occurs" in standard FMEA conventions, but the ADR does not define the 1-10 scale for any of the three FMEA dimensions. Without the scale definition, the RPN values are correctly computed but the individual S/O/D ratings cannot be audited.

2. The Options Evaluation Summary (lines 194-198) assigns "Phase 2 Compatibility = HIGHEST" to Option 3 (defer all), which is technically correct (no changes = no contamination) but could be read as implying Option 3 has high value in this dimension rather than simply high avoidance. A clarifying note would prevent misreading.

**Improvement Path:**

Add a footnote or inline definition of the FMEA Severity/Occurrence/Detection 1-10 scale (e.g., "Detection: 1=immediate detection by quality gate, 10=not detectable until production impact"). This is a one-sentence addition per dimension. Add a parenthetical to Option 3's "HIGHEST" Phase 2 Compatibility score clarifying that this reflects zero-change avoidance, not positive Phase 2 support.

---

### Evidence Quality (0.90/1.00)

**Evidence:**

The evidence quality framework is appropriately tiered:
- T1: A-20 (AAAI 2026), A-15 (EMNLP 2024) — peer-reviewed venues, both confirmed present in barrier-2/synthesis.md.
- T3: A-31 (arXiv preprint) — correctly labeled as lower tier than T1.
- T4: VS-001 through VS-004, TASK-012 through TASK-015 — compiled inventories and observational evidence, correctly labeled.
- UNTESTED: NPT-009 vs. positive framing at ranks 9-11 — correctly labeled in evidence tier table at line 444.

The MANDATORY EPISTEMOLOGICAL BOUNDARY is not a hedging note — it is a structural constraint that the ADR enforces rigorously. No claim in the document asserts that NPT-009 outperforms positive equivalents.

A-11 is absent. AGREE-5 is not presented as T1 or T3 evidence. PG-001 "HIGH unconditional confidence" is correctly sourced to barrier-2/synthesis.md ST-4, which labels it "What is established (HIGH confidence, usable NOW)."

The "+7-8% compliance improvement" claim (from A-15, EMNLP 2024) is correctly attributed and tier-labeled (T1). The claim is consistent with barrier-2/synthesis.md's characterization of A-15.

**Gaps:**

1. **Bibliographic opacity for A-20, A-15, A-31.** The reference table (lines 482-496) identifies these sources by evidence code, venue, and year only. No author, title, or DOI is provided. For a C4 ADR, the two T1 sources (A-20, A-15) that establish the core claim should be identifiable independently of the upstream evidence catalog (barrier-1 findings files). The ADR currently requires a reader to read the barrier-1 survey files to get the full citation. This is a traceability-evidence boundary issue: the references section satisfies traceability (you can find the source) but not full evidence quality (you cannot independently verify A-20 = specific AAAI 2026 paper without additional lookups).

2. **VS-001 through VS-004 structural opacity.** The reference entry for VS-001 through VS-004 is grouped ("supplemental-vendor-evidence.md (R4, 0.951 PASS)") but the individual VS codes represent distinct vendor observations (Anthropic's practice patterns documented across 10 rule files). The grouping is appropriate but a brief disambiguation of VS-001 vs. VS-003 would strengthen the evidence table, since both are cited individually in the body of the document.

**Improvement Path:**

For A-20 and A-15 specifically: add full citation (author last name, title, venue, year, DOI if available) to the References section. These are the two T1 evidence anchors for the entire ADR's core claim — they deserve full bibliographic treatment. For VS-001 through VS-004: add a parenthetical distinguishing the codes (e.g., "VS-001: NEVER/MUST NOT instance catalog (33 instances); VS-003: HARD tier vocabulary observation").

---

### Actionability (0.91/1.00)

**Evidence:**

The ADR provides actionable implementation content at multiple levels:

- **Diagnostic filter** (lines 233-240): Binary test for NPT-014 identification. An implementer can apply this without additional clarification.
- **5-step upgrade procedure** (lines 244-266): Identify → Document Consequence → Specify Scope → Add Alternative → Validate. Each step includes sub-guidance (sources for consequence documentation, scope pattern examples).
- **Conversion examples** (lines 79-82): Before/after table with two concrete examples showing exactly what an upgraded constraint looks like.
- **4-group sequencing** (lines 270-289): Ordered implementation groups with rationale, instance counts, and dependency chain (TASK-012 → TASK-011 → TASK-010).
- **Phase 2 baseline preservation protocol** (lines 292-298): 4 numbered steps with specific actions.
- **L2 token budget analysis** (lines 300-302): Arithmetic showing worst-case 87.6% budget utilization.
- **FMEA mitigations** (lines 359-366): Each failure mode has a specific mitigation action.
- **Pre-mortem mitigations** (lines 349-355): Each failure scenario has a specific operational response.

The ADR explicitly directs downstream work: "Next Agent Hint: ps-architect for ADR-002; implementation planning agent for Group 1-4 sequencing."

**Gaps:**

1. **Group 2 count ambiguity impacts implementation planning.** The implementation section says Group 2 = "27 agent-level + 5 framework-level" but the barrier-4/synthesis.md source document (TASK-011 row) says "32 recommendations across 9 agent families." The "5 framework-level" sub-category is not defined — it is not clear whether these 5 are a subset of the 32 or an additional 5 (which would make Group 2 = 37, not 32). This ambiguity could cause an implementer to miscount their scope. Based on context, 27+5=32 appears to match the TASK-011 total, but the distinction is never explained.

2. **Validation step (Step 5) for the upgrade procedure does not include a quality gate hook.** Step 5 checks that consequence/scope/alternative are present but does not specify where or how the validation result is recorded. The FMEA section notes "NPT-014 diagnostic in quality gate; template update" as the mitigation for new-NPT-014-introduction risk (RPN 150), but the upgrade procedure itself does not cross-reference this. A single sentence connecting Step 5 to the H-17 quality gate would complete the implementation loop.

**Improvement Path:**

Clarify in Group 2 description that the 5 "framework-level" recommendations are a subset of the 32 TASK-011 recommendations (or if they are additional, state that explicitly). Add one sentence to Step 5 connecting the validation check to H-17 (quality scoring) and the NPT-014 diagnostic integration.

---

### Traceability (0.93/1.00)

**Evidence:**

All major claims trace to specific upstream documents:
- PG-001 → barrier-2/synthesis.md ST-4
- 22 NPT-014 instances in rule files → TASK-012 (rules-update-analysis.md)
- 130 total recommendations → barrier-4/synthesis.md L0
- 5-domain universal NPT-014 presence → barrier-4/synthesis.md Themes 1 and 2
- Phase 2 unconditional exception → barrier-4/synthesis.md Section 3 (quoted: "Exception: NPT-014 elimination (PG-001 unconditional, T1+T3 HIGH)")
- Constraint propagation (GC-P4-1, GC-P4-2, GC-P4-3) → barrier-2/synthesis.md ST-5

The constraint table (C-001 through C-007) includes source citations for each constraint. The evidence tier table in Compliance maps each claim to tier and source. The PS Integration section provides worktracker linkage (PROJ-014, TASK-016). References section has 13 entries with type and relevance classification.

**Gaps:**

1. **The "5 framework-level" category in Group 2 lacks a source.** The 27 "agent-level" recommendations presumably trace to TASK-011, but the 5 "framework-level" recommendations have no specified source artifact. If they come from TASK-012 (which discusses agent-development-standards.md as a rule file containing the NPT-014 minimum example), that should be stated. If they come from a cross-cutting theme in barrier-4/synthesis.md, that should be cited.

2. **The option scoring rubric (9/10, 6/10, 3/10) lacks source traceability.** These are evaluative judgments made by the ADR author, not derived from a specific upstream scoring template. For a C4 ADR, it is appropriate for the architect to assign option scores, but a sentence explaining the basis (even if explicitly "architect's synthesis judgment") would acknowledge the traceability gap honestly.

**Improvement Path:**

Add a source citation for the "5 framework-level" agent recommendations in Group 2. Add a footnote to the Options Evaluation Summary clarifying that scores are architect's synthesis judgment derived from the evaluation criteria in the three columns.

---

## Improvement Recommendations (Priority Ordered)

| Priority | Dimension | Current | Target | Recommendation |
|----------|-----------|---------|--------|----------------|
| 1 | Evidence Quality | 0.90 | 0.93 | Add full bibliographic citations (author, title, DOI) for A-20 (AAAI 2026) and A-15 (EMNLP 2024) in the References section. These are the T1 anchors for the core claim and should be independently verifiable. |
| 2 | Internal Consistency | 0.91 | 0.94 | Consolidate or clearly differentiate the Pre-Mortem table (L2 section) and the Consequences: Risks table. Either merge into a single risk register or add a header note explaining distinct scope (methodology vs. formal risk register). |
| 3 | Actionability | 0.91 | 0.93 | Clarify the Group 2 "27 agent-level + 5 framework-level" breakdown — confirm these sum to the TASK-011 total of 32 and specify what "framework-level" means. Add a source citation for the 5 framework-level entries. |
| 4 | Methodological Rigor | 0.93 | 0.95 | Add a one-line scale definition for the FMEA Severity/Occurrence/Detection 1-10 dimensions. Without the scale, the individual S/O/D values cannot be independently audited even though the RPN arithmetic is correct. |
| 5 | Traceability | 0.93 | 0.95 | Source the "5 framework-level" Group 2 recommendations to their specific artifact (TASK-011, TASK-012, or a specific barrier-4/synthesis.md section). |
| 6 | Completeness | 0.93 | 0.95 | Optionally add a compact enumeration of the 6 rule-file recommendations (R-QE-001 through R-ADS-003) in the L1 section, reducing the implementation dependency on TASK-012 for initial orientation. |

**Score impact estimate:** Implementing recommendations 1-4 (the four highest-priority items) would close the gap between the current 0.9185 score and the 0.95 C4 threshold. Items 5-6 provide additional margin. Recommendations 1 and 2 together account for most of the gap because they are the primary drivers of the Evidence Quality (0.90) and Internal Consistency (0.91) scores, which are the two lowest-scoring dimensions.

---

## ADR-Specific Gate Check Summary

| Gate | Check | Result | Notes |
|------|-------|--------|-------|
| GC-ADR-1 | Nygard format complete | PASS | Title, Status, Context, Decision, Consequences all present; extended format |
| GC-ADR-2 | Evidence tier labels present | PASS WITH GAP | Labels correct throughout; A-20/A-15/A-31 lack full bibliographic data |
| GC-ADR-3 | PG-003 reversibility documented | PASS | Full 5-component table; HIGH overall; PG-003 null-framing contingency present |
| GC-ADR-4 | Phase 2 dependency handled | PASS | Unconditional status explained with 3 independent citations; "Phase 2 outcome irrelevant" explicitly stated |
| GC-ADR-5 | No false validation claims | PASS | MANDATORY EPISTEMOLOGICAL BOUNDARY enforced; UNTESTED labels applied; A-11 absent |

---

## Leniency Bias Check

- [x] Each dimension scored independently before composite computed
- [x] Evidence documented for each score — specific line numbers and content cited
- [x] Uncertain scores resolved downward (Internal Consistency: considered 0.92, scored 0.91 due to Pre-Mortem/Risks redundancy)
- [x] C4 threshold (0.95) held firm — score of 0.9185 is correctly below threshold
- [x] No dimension scored above 0.95 — highest is 0.93 (three dimensions)
- [x] First-draft calibration considered — this is I1; the 0.9185 score is appropriate for a high-quality first-draft ADR that needs specific targeted improvements
- [x] FMEA arithmetic independently verified (all 5 RPN values checked)
- [x] L2 token budget arithmetic independently verified (745/850 = 87.6% confirmed correct)
- [x] A-11 absence confirmed (zero occurrences searched)
- [x] AGREE-5 over-citation checked — correctly labeled as internally generated, not cited as T1/T3

---

## Session Context (Handoff Schema)

```yaml
verdict: REVISE
composite_score: 0.9185
threshold: 0.95
standard_threshold: 0.92
weakest_dimension: Evidence Quality
weakest_score: 0.90
critical_findings_count: 0
iteration: 1
distance_from_threshold: 0.0315
top_gap_dimensions:
  - Evidence Quality (0.90): missing full bibliographic citations for T1 anchors A-20, A-15
  - Internal Consistency (0.91): Pre-Mortem / Consequences:Risks redundancy; option scoring scale undefined
  - Actionability (0.91): Group 2 framework-level count ambiguity; Step 5 missing quality gate hook
improvement_recommendations:
  - "Add full citation (author, title, DOI) for A-20 and A-15 in References section"
  - "Consolidate or differentiate Pre-Mortem table and Consequences:Risks table"
  - "Clarify Group 2 breakdown: confirm 27+5=32 and define 'framework-level'; add source citation"
  - "Add FMEA scale definitions for Severity/Occurrence/Detection 1-10 dimensions"
  - "Source the 5 framework-level Group 2 recommendations to specific artifact"
  - "Optionally enumerate R-QE-001 through R-ADS-003 in L1 section"
gate_checks_passed: [GC-ADR-1, GC-ADR-2, GC-ADR-3, GC-ADR-4, GC-ADR-5]
gate_checks_with_gaps: [GC-ADR-2]
blocking_findings: none
arithmetic_verified: true
```

---

*Scored by: adv-scorer*
*Strategy: S-014 (LLM-as-Judge, 6-dimension weighted composite)*
*Criticality: C4 (threshold 0.95)*
*SSOT: `.context/rules/quality-enforcement.md`*
*Workflow: neg-prompting-20260227-001*
*Task: TASK-016 (phase-5 ADR scoring, I1)*
*Created: 2026-02-28*
